Session Description: 

This activity is a journal club which is used to facilitate an evidence-based approach to problem solving, as a tool for informing guideline development and to enable an exchange of insights regarding clinical problems related to degenerative lumbar pathologies. In this session, the physician team will be current state of the science on long-term outcomes following CAR-T Cell Therapy.

Target Audience: 

Physicians (MD or DO)

Learning Objectives- After Attending this Activity, Learners Should be Able to:

1. Critically review current evidence on the efficacy and safety of CAR/T cells data from clinical trials and post-commercial studies.

2. Summarize patient selection criteria for available therapies.

3. Discuss management of the long-term side effects after CAR-T therapy.

4. Apply strategies for prompt referral and optimal coordination between CAR-T cell treatment center and community practice.

Providing Culturally Appropriate Care which is Free of Implicit Biases (AB 1195 & 241):

  • Vea, M., Erondu, A., Smith, N., Peek, M., Woodruuf, J., & Chin, M. (2022). Eliminating explicit and implicit biases in healthcare: Evidence and research needs. Annu Rev Public Health;43: 477-501. doi: 10.1146/annurev-publhealth-052620-103528

  • Hall, A., Winestone, L., Sullivan, E., Wu, Q., Lamble, A., Walters, M., Aguayo-Hiraldo, P., Conde, L., Coker, T., Dornsife, D., Keating, A., Merino, D., Ramsey, B., Park, J., & Agrawal, A. (2023). Access to chimeric antigen receptor T cell clinical trials in underrepresented populations: A multicenter cohort study of pediatric and young adult acute lymphobastic leukemia patients. Science Direct; 29 (6). doi: https://doi.org/10.1016/j.jtct.2023.03.022

  • Rouce, R. & Nemecek, E. (2023). Access offsets poverty in quest for CAR T cells. Blood; 141 (6). Doi: https://doi.org/10.1182/blood.2022018552

Disclosure of Financial or In-Kind Commercial Support & Conflict of Interest

Oleg Krijanovski, faculty for this presentation, receives speaker fees from Incyte (re: Jakafi) and CTI BioPharma (re: Pacritinib). These ineligible financial relationships were deemed to be not directly relevant to the topic of long-term outcomes of CAR-T cell therapy; however, Dr. Krijanovski has completed a Speaker Agreement Form as a form of good faith mitigation for these disclosed relationships.

No one else involved in the planning or presentation of this educational activity have any relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. No financial or in-kind commercial support was received to produce or promote this educational activity.   

– Provider Designee/Verification:  Kerri Maya, PhD(c), MSL, RN, NPD-BC

Session date: 
09/11/2023 - 5:30pm to 7:00pm PDT
Add to calendar: 
  • 1.50 AMA PRA Category 1 Credit™

    Physician Credit 

    Sutter Health designates this Live activity for a maximum of 1.50 AMA PRA Category 1 Credit™ for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

  • 1.50 Non-Physician Participation Credit

    Sutter Health designates this Live activity for a maximum of 1.50 Non-Physician Participation Credit. Non-Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMA PRA Category 1 Credits HOURS™ Continuing Medical Education is acceptable for meeting the continuing education requirements for Pharmacists, Physician Assistants, Psychologists, Registered Nurses, and Respiratory Care Practitioners. For other disciplines, please check with the regulatory board for your discipline to confirm what type of credits meet the continuing education requirements. Continuing education hours for nurses accredited by ANCC, via Joint Accreditation.

     

Please login or register to take this course.